Autoimmune diseases (ADs) pose a significant health burden among adolescents and young adults (AYAs) in Mexico. However, comprehensive national epidemiological data remain limited. This study evaluates the prevalence, incidence, and mortality of six major AD: rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), asthma, and psoriasis, utilizing data from the Global Burden of Disease Study 2021. Age-standardized rates were calculated through direct standardization using the GBD 2021 world standard population. Temporal trends from 1990 to 2021 were analyzed via Joinpoint regression, which determined each condition’s average annual percentage change (AAPC). Additionally, an ARIMA model was employed to forecast trends for the period from 2022 to 2035. In 2021, RA exhibited an age-standardized prevalence rate (ASPR) of 45.67, an incidence rate (ASIR) of 9.07, and a mortality rate (ASMR) of 0.02 per 100,000 inhabitants, with a marked female predominance and notable regional disparities. IBD showed low prevalence and incidence but a rising mortality trend, particularly in areas with enhanced diagnostic capacities. MS demonstrated increasing prevalence and incidence, especially among females. T1DM presented high prevalence and incidence, with declining trends over time accompanied by a gradual rise in mortality. Asthma remained highly prevalent despite overall declining trends, while psoriasis maintained a stable incidence with a considerable prevalence among AYAs. The findings highlight significant regional and sex-related disparities in the burden of ADs among Mexican AYAs. Forecasting analyses predict moderate increases in RA and MS, stability in IBD, asthma, and psoriasis, and a decline in T1DM prevalence and incidence, albeit with a slight increase in mortality. These results emphasize the urgent need for targeted public health interventions, improved diagnostic strategies, and equitable healthcare provision to mitigate the future impact of ADs in this vulnerable population.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

https://www.healthdata.org/research-analysis/gbd

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors